

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

NCT06185764

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Vertex Pharmaceuticals Incorporated
Enrollment	44 participants

Key Eligibility Criteria

Inclusion (1)

- Documented clinical diagnosis of DM1 with age of onset greater than (>) 1 year of age and documented positive genetic test for DM1 in the subject with cytosine thymine guanine (CTG) repeat of at least 100

Exclusion (1)

- History of any illness or any clinical condition as pre-specified in the protocol

Locations (26 total)

Stanford Neuromuscular Research, San Carlos, California, United States
University of Florida Clinical Research Center, Gainesville, Florida, United States
University of Kansas Medical Center, Fairway, Kansas, United States
... and 23 more locations